Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125150) titled 'Efficacy and safety of Serplulimab combined with platinum-based chemotherapy and H1 receptor antagonist (desloratadine) in the First-line Treatment for locally advanced or metastatic non-small cell lung cancer:a prospective randomized controlled study' on May 21.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Ningbo Medical Centre Lihuili Hospital
Condition:
Non-small cell lung cancer
Intervention:
Experimental group:Desloratadine
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-03
Target Sample Size: Experimental group:60;Control group:60;
Count...